Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?
- PMID: 30632052
- DOI: 10.1007/s10620-018-5450-4
Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?
Abstract
Introduction: The risk of a new Clostridium difficile infection (CDI) after FMT is unknown if non-CDI antibiotics are required. It is uncertain if anti-CDI prophylaxis or probiotics would reduce risk. We therefore aimed to compare the risk of CDI with and without antibiotic exposure and the benefit of concomitant anti-CDI antibiotic or probiotic prophylaxis.
Methods: This is a multicenter retrospective study carried out at three large FMT referral centers of patients who underwent FMT for recurrent CDI. Patients were assessed for antibiotic use, as well as concomitant use of prophylactic anti-CDI antibiotics or probiotics. Time to CDI recurrence after FMT was evaluated using the Kaplan-Meier method.
Results: A total of 404 patients were included: 63% were females, with a mean age of 61.3 ± 18.8 years. Mean length of post-FMT follow-up was 18.1 ± 11.9 months (range 2.2-45.2). Among the entire cohort 8.1% (n = 33) experienced a CDI recurrence. Overall, 111 patients (27.4%) used a non-CDI antibiotic, of which 16.2% (n = 18) experienced a CDI recurrence. Patients who used non-CDI antibiotics were more likely to develop CDI (HR 8.44, 95% CI 4.21-16.93, p < 0.001). The risk of CDI recurrence was not different between patients who received anti-CDI antibiotic prophylaxis to those who did not (HR = 1.88, 95% CI 0.72-4.86, p = 0.2); however, probiotic prophylaxis was associated with a greater risk of CDI recurrence (HR = 2.65, 95% CI 1.02-6.86, p = 0.045).
Conclusion: Non-CDI antibiotic use was not uncommon after successful FMT and significantly increased the risk of a new episode of CDI. In this study, we found that the prophylactic use of anti-CDI antibiotics or probiotics was not protective.
Keywords: C. difficile recurrence prevention; Clostridium difficile infection; FMT; Fecal microbiota transplantation; Systemic antibiotic.
Similar articles
-
Fecal microbiota transplantation (FMT) for C. difficile infection, just say 'No'.Anaerobe. 2019 Dec;60:102092. doi: 10.1016/j.anaerobe.2019.102092. Epub 2019 Aug 28. Anaerobe. 2019. PMID: 31472233 Review.
-
Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience.J Clin Gastroenterol. 2016 May-Jun;50(5):398-402. doi: 10.1097/MCG.0000000000000374. J Clin Gastroenterol. 2016. PMID: 26125460
-
Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.Transpl Infect Dis. 2016 Aug;18(4):628-33. doi: 10.1111/tid.12550. Epub 2016 Jul 5. Transpl Infect Dis. 2016. PMID: 27214585 Clinical Trial.
-
Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1731-1735. doi: 10.1007/s10096-019-03602-2. Epub 2019 Jun 5. Eur J Clin Microbiol Infect Dis. 2019. PMID: 31165961
-
Fecal microbiota transplantation for the treatment of Clostridium difficile infection.J Hosp Med. 2016 Jan;11(1):56-61. doi: 10.1002/jhm.2449. Epub 2015 Sep 7. J Hosp Med. 2016. PMID: 26344412 Free PMC article. Review.
Cited by
-
Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation.Anaerobe. 2021 Aug;70:102387. doi: 10.1016/j.anaerobe.2021.102387. Epub 2021 May 24. Anaerobe. 2021. PMID: 34044101 Free PMC article.
-
The Current Knowledge on Clostridioides difficile Infection in Patients with Inflammatory Bowel Diseases.Pathogens. 2022 Jul 21;11(7):819. doi: 10.3390/pathogens11070819. Pathogens. 2022. PMID: 35890064 Free PMC article. Review.
-
Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis.Clin Gastroenterol Hepatol. 2021 Aug;19(8):1627-1634. doi: 10.1016/j.cgh.2020.06.051. Epub 2020 Jul 6. Clin Gastroenterol Hepatol. 2021. PMID: 32645451 Free PMC article.
-
Clostridioides difficile therapeutics: guidelines and beyond.Ther Adv Infect Dis. 2019 Aug 13;6:2049936119868548. doi: 10.1177/2049936119868548. eCollection 2019 Jan-Dec. Ther Adv Infect Dis. 2019. PMID: 31448117 Free PMC article. Review.
-
A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Hepatic Encephalopathy and Clostridioides difficile Infection in Patients With Cirrhosis.Cureus. 2022 May 31;14(5):e25537. doi: 10.7759/cureus.25537. eCollection 2022 May. Cureus. 2022. PMID: 35800791 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical